SLRN vs. TRDA, OCS, ANL, FULC, LXRX, ANNX, LRMR, TVTX, TBPH, and CRBP
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Entrada Therapeutics (TRDA), Oculis (OCS), Adlai Nortye (ANL), Fulcrum Therapeutics (FULC), Lexicon Pharmaceuticals (LXRX), Annexon (ANNX), Larimar Therapeutics (LRMR), Travere Therapeutics (TVTX), Theravance Biopharma (TBPH), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical preparations" industry.
Entrada Therapeutics (NASDAQ:TRDA) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.
Entrada Therapeutics has a net margin of 14.42% compared to Entrada Therapeutics' net margin of 0.00%. Acelyrin's return on equity of 9.73% beat Entrada Therapeutics' return on equity.
Entrada Therapeutics and Acelyrin both received 11 outperform votes by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 61.11% of users gave Acelyrin an outperform vote.
Entrada Therapeutics has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Acelyrin had 7 more articles in the media than Entrada Therapeutics. MarketBeat recorded 11 mentions for Acelyrin and 4 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.97 beat Acelyrin's score of 0.70 indicating that Acelyrin is being referred to more favorably in the news media.
86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by company insiders. Comparatively, 13.6% of Acelyrin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Entrada Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 39.26%. Acelyrin has a consensus target price of $21.67, indicating a potential upside of 403.88%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Acelyrin is more favorable than Entrada Therapeutics.
Summary
Entrada Therapeutics beats Acelyrin on 9 of the 15 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
